We performed targeted bulk metabolomics in plasma samples from Mdm2-cKO (n = 12) versus control (n = 9) mice, at day 6 of doxycycline administration, with a panel of 32 amino acid–related metabolites relevant to human kidney disease, based on a prior untargeted metabolomics analysis from over 1,000 patients (15). The gene discussed is MDM2; the disease is kidney disorder.